DCOY

Decoy Therapeutics Inc

9.59

Jun 29 • 04:00PM ET +4.07 (73.79%)

Healthcare Biotechnology USA Nano NASD

Today, 8:30 PM$21M milestone-based PIPE financing drives 74% surge in DCOY shares

Peers: APRE BCDA BIVI CALC CVM GOVX KAPA KPRX LNAI NEUP

| Held by: VXF MEDX

Scroll to Statements

Index	-
Market Cap	5.11M
Enterprise Value	-2.71M
Income	-13.03M
Sales	0.00M
Book/sh	7.29
Cash/sh	14.68
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	11
IPO	Jan 29, 2015

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	1.32
P/C	0.65
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	1.84
Current Ratio	1.84
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	No / No

EPS (ttm)	-124.04
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	81.80% 62.32%
Sales past 3/5Y	- -
EPS Y/Y TTM	86.68%
Sales Y/Y TTM	-
EPS Q/Q	97.74%
Sales Q/Q	-
Earnings	Mar 30
EPS/Sales Surpr.	- -

Insider Own	3.52%
Insider Trans	-0.14%
Inst Own	11.40%
Inst Trans	-31.00%
ROA	-242.20%
ROE	-661.73%
ROIC	-336.14%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	46.46%
SMA50	55.42%
SMA200	-42.32%
Trades

Shs Outstand	0.53M
Shs Float	0.51M
Short Float	0.39%
Short Ratio	0.10
Short Interest	0.00M
52W High	415.80 -97.69%
52W Low	4.32 121.99%
Volatility	15.60% 14.90%
ATR (14)	1.21
RSI (14)	71.15
Beta	0.66
Rel Volume	678.15
Avg Volume	18.77K
Volume	12,728,152

Perf Week	52.22%
Perf Month	21.24%
Perf Quarter	52.22%
Perf Half Y	25.66%
Perf YTD	23.18%
Perf Year	-94.62%
Perf 3Y	-99.50%
Perf 5Y	-99.98%
Perf 10Y	-100.00%
Recom	1.00
Target Price	30.00
Prev Close	5.52
Price	9.59
Change	73.79%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-23-26	Initiated	Ladenburg Thalmann	Buy	$2.50
Apr-27-20	Initiated	Ladenburg Thalmann	Buy	$3.80

Today 11:41AM	DCOY Stock Nearly Doubled In Value Today Whats Driving This Mega Rally? (Stocktwits) +73.79%
Jun-26-26 08:11PM	Decoy Therapeutics, Inc. Announces Up to $21 Million Private Placement Financing (PR Newswire) -6.76%
Jun-08-26 08:00AM	Decoy Therapeutics' CEO to Participate in hVIVO Capital Markets Day in London (PR Newswire) -5.45%
Jun-03-26 08:00AM	Decoy Therapeutics Nominates Global Biopharma Executive Patricia Gauthier for Election to Board of Directors (PR Newswire) -7.43%
Jun-01-26 07:00AM	Decoy Therapeutics Partners with hVIVO to Advance Lead D-MAV Candidate into the Clinic (PR Newswire) -6.28%
08:15AM	Loading…
May-26-26 08:15AM	Decoy Therapeutics Names Brad Pentelute, MIT Professor of Chemistry, as Chair of Scientific Advisory Board (PR Newswire)
May-08-26 04:53PM	Decoy Therapeutics: Q1 Earnings Snapshot (Associated Press)
Apr-27-26 08:45AM	Decoy Therapeutics to Present at Two Peptide Therapeutics Conferences in Boston (PR Newswire)
Apr-09-26 08:36AM	Decoy Therapeutics Builds Momentum with Accelerating Execution, Entering a Highly Catalytic Phase with a Clearly Defined Path to Clinical Development of its Antiviral Pipeline (PR Newswire) +6.57%
Apr-06-26 09:15AM	Decoy Therapeutics to Participate in Virtual Investor Closing Bell Event Highlighting Business Outlook for 2026 (PR Newswire)
Apr-02-26 09:00AM	Decoy Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement (PR Newswire) -8.23%
Mar-11-26 08:30AM	Decoy Therapeutics Enters Strategic Partnership with Quantori to Deploy Google Cloud-native Integrated AI-Driven Peptide Design and Molecular Simulation Platform (PR Newswire)
Mar-05-26 08:30AM	Decoy Therapeutics Announces 1-for-12 Reverse Stock Split (PR Newswire) -11.34%
Feb-11-26 09:00AM	Decoy Therapeutics Joins Webull Corporate Connect Service Platform (PR Newswire)
Feb-05-26 09:15AM	Decoy Therapeutics to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial (PR Newswire)
09:02AM	Loading…
Feb-04-26 09:02AM	Decoy Therapeutics Participates in Virtual Investor "What This Means" Segment Highlighting Recently Announced Global Access Commitment Agreement (PR Newswire) -7.62%
Jan-13-26 08:15AM	Decoy Therapeutics Reaches Global Access Commitment Agreement to Focus on Development of a Globally Accessible, Scalable Peptide-Conjugate Manufacturing Platform (PR Newswire) +53.37%
Jan-07-26 08:45AM	Salarius Pharmaceuticals Changes Corporate Name to Decoy Therapeutics and Nasdaq Ticker Symbol to DCOY Reflecting Focus on Next-Generation Peptide Conjugate Therapeutics (GlobeNewswire) +29.23%
Dec-19-25 11:12AM	Salarius Pharmaceuticals Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting (GlobeNewswire)
Dec-18-25 07:50AM	Salarius Pharmaceuticals Announces Planned Corporate Name and Ticker Symbol Change to Decoy Therapeutics, Reflecting Strategic Pivot to Next-Generation Antiviral and Peptide-Conjugate Platform (GlobeNewswire)
Dec-01-25 08:00AM	Salarius Pharmaceuticals to Collaborate with Texas Biomedical Research Institute on Avian Flu Study (GlobeNewswire) -7.41%
Nov-19-25 02:42PM	Salarius Pharmaceuticals Cites Errors on S&P CapIQ Platform Following Merger with Decoy Therapeutics, Affirms Its Shares Continue to Trade on the Nasdaq Stock Market Under the Symbol "SLRX" (GlobeNewswire) -8.32%
Nov-14-25 05:35PM	Salarius: Q3 Earnings Snapshot (Associated Press Finance) -23.41%
Nov-13-25 08:45AM	Salarius Pharmaceuticals and Decoy Therapeutics Complete Merger (GlobeNewswire) +5.22%
Nov-11-25 09:18AM	Salarius Pharmaceuticals Announces Pricing of $7 Million Underwritten Public Offering (PR Newswire) -51.00%
Oct-13-25 08:45AM	Salarius Pharmaceuticals Regains Compliance with All Nasdaq Listing Requirements (GlobeNewswire)
Sep-09-25 08:00AM	Salarius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire)
Aug-14-25 08:30AM	Salarius Pharmaceuticals Announces 1-for-15 Reverse Stock Split (GlobeNewswire) -6.43%
Aug-12-25 05:35PM	Salarius: Q2 Earnings Snapshot (Associated Press Finance) -12.04%
Jul-29-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +34.88%
08:30AM	Loading…
Jul-14-25 08:30AM	Salarius Pharmaceuticals Granted Additional Extension to Regain Compliance with Nasdaq's Stockholders' Equity Standard (GlobeNewswire) -9.36%
Jul-09-25 08:30AM	Salarius Pharmaceuticals' Seclidemstat Demonstrates Supporting Role in Inhibiting Validated Oncology Target LSD1 in Two Recently Published Studies (GlobeNewswire)
May-14-25 05:33PM	Salarius: Q1 Earnings Snapshot (Associated Press Finance) +11.53%
Apr-16-25 08:00AM	Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Appoints Renowned MIT Professor Robert S. Langer to its Scientific Advisory Board (GlobeNewswire) -6.71%
Mar-26-25 08:00AM	Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Announces its Novel Inhibitors Show Promising In Silico Activity Against Measles and Related Viruses (GlobeNewswire) -9.78%
Mar-24-25 08:00AM	Salarius Pharmaceuticals Reports 2024 Financial Results and Provides Business Update (GlobeNewswire)
Feb-03-25 08:00AM	Salarius Pharmaceuticals Announces Patient Enrollment to Resume in Investigator-initiated Phase 1/2 Clinical Trial Using Seclidemstat with Azacitidine to Treat Hematologic Cancers (GlobeNewswire)
Jan-13-25 08:00AM	Salarius Pharmaceuticals and Decoy Therapeutics Announce Definitive Merger Agreement (GlobeNewswire) +134.50%
Nov-14-24 07:25PM	Salarius: Q3 Earnings Snapshot (Associated Press Finance)
Aug-09-24 05:21PM	Salarius: Q2 Earnings Snapshot (Associated Press Finance) +11.65% -5.22%
Jul-11-24 07:29AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday (InvestorPlace) -20.51%
Jun-17-24 08:00AM	Clinical Data on Salarius Pharmaceuticals' Seclidemstat in Patients with MDS and CMML Presented at the 2024 European Hematology Association Annual Meeting (GlobeNewswire)
Jun-12-24 08:00AM	Salarius Pharmaceuticals Announces 1-for-8 Reverse Stock Split (GlobeNewswire)
May-13-24 10:53PM	SLRX Stock Earnings: Salarius Pharmaceuticals Beats EPS for Q1 2024 (InvestorPlace) -7.12%
04:43PM	Salarius: Q1 Earnings Snapshot (Associated Press Finance)
Mar-22-24 09:52PM	SLRX Stock Earnings: Salarius Pharmaceuticals Beats EPS for Q4 2023 (InvestorPlace) +5.96% -17.74%
04:34PM	Salarius: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Feb-22-24 08:00AM	Salarius Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expenses (GlobeNewswire)
Jan-16-24 08:00AM	Salarius Pharmaceuticals Issued U.S. Patent for Next-Generation Targeted Protein Degraders (GlobeNewswire)
Jan-03-24 08:30AM	Investigator-initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals' Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Resumes Patient Enrollment (GlobeNewswire)
Nov-10-23 05:03AM	Salarius: Q3 Earnings Snapshot (Associated Press Finance)
Nov-07-23 08:30AM	Salarius Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Program (GlobeNewswire)
Aug-10-23 05:10PM	Salarius: Q2 Earnings Snapshot (Associated Press Finance) -9.32% -5.92%
04:05PM	Salarius Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides a Business Update (GlobeNewswire)
Aug-09-23 07:39AM	SLRX Pursuing Strategic Alternatives (Zacks) -9.96%
Aug-08-23 04:05PM	Salarius Pharmaceuticals Announces Plans to Explore Strategic Alternatives and Implement Measures to Extend its Resources (GlobeNewswire)
Jul-11-23 09:00AM	SLRX Continues Cancer Fight with Phase I Trial Approval (Zacks) -12.41%
08:30AM	Salarius Pharmaceuticals Receives FDA Clearance of SP-3164 Investigational New Drug Application to Begin a Phase 1 Clinical Trial in Relapsed/Refractory Non-Hodgkin Lymphoma Patients (GlobeNewswire)
Jun-12-23 08:00AM	Salarius Pharmaceuticals Presents SP-3164 Targeted Protein Degrader Preclinical Data at the European Hematology Association 2023 Hybrid Congress (GlobeNewswire)
May-16-23 04:05PM	Salarius Pharmaceuticals Announces Closing of $6 Million Private Placement Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
May-12-23 08:00AM	Salarius Pharmaceuticals Announces $6 Million Private Placement Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
May-11-23 08:20AM	Salarius: Q1 Earnings Snapshot (AP Finance) -5.41%
08:00AM	Salarius Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides a Business Update (GlobeNewswire)
May-09-23 08:00AM	FDA Removes Partial Clinical Hold on Salarius Pharmaceuticals Phase 1/2 Clinical Trial with Seclidemstat in Patients with Ewing Sarcoma (GlobeNewswire) -16.20%
07:34AM	SLRX: Fighting Cancer Through Two Paths (Zacks Small Cap Research)
May-01-23 08:30AM	Salarius Pharmaceuticals Reports No Adverse Safety Signals from Two Good Laboratory Practice Toxicology Studies with its Targeted Protein Degrader SP-3164 (GlobeNewswire)
Apr-20-23 08:30AM	Salarius Pharmaceuticals Presents Compelling Data in Two SP-3164 Targeted Protein Degrader Posters at the American Association for Cancer Research Annual Meeting (GlobeNewswire) -10.75%
Apr-04-23 04:02PM	Salarius Pharmaceuticals to Present at the Diamond Equity Research Emerging Growth Invitational Conference (GlobeNewswire) -12.32% -5.48%
12:00PM	Diamond Equity Research to Host Spotlight Emerging Growth Invitational Virtual Investor Conference on April 5, 2023 (GlobeNewswire)
Mar-27-23 08:30AM	Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update (GlobeNewswire)
Mar-15-23 11:00AM	Salarius Pharmaceuticals Announces Two Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting (GlobeNewswire)
Mar-07-23 08:00AM	Salarius Pharmaceuticals to Present In Vitro Data on Seclidemstat in Small Cell Lung Cancer at the Keystone Symposia (GlobeNewswire)
Feb-16-23 08:30AM	Salarius Pharmaceuticals Receives $1.48 Million from the Cancer Prevention and Research Institute of Texas (GlobeNewswire)
Jan-27-23 08:30AM	Salarius Pharmaceuticals Presents SP-3164 Preclinical Data at the Inaugural Molecular Glue Drug Development Summit (GlobeNewswire) -5.47%
Jan-19-23 08:30AM	Salarius Pharmaceuticals to Present SP-3164 Targeted Protein Degrader Preclinical Data at the Inaugural Molecular Glue Drug Development Summit (GlobeNewswire) +52.99%
Jan-05-23 08:00AM	Salarius Pharmaceuticals Announces Issuance of New U.S. Patent for Next-Generation Targeted Protein Degraders (GlobeNewswire)
Dec-13-22 08:01AM	Investigators Present Clinical Data on Salarius Pharmaceuticals Seclidemstat in Patients with MDS and CMML at the 2022 American Society of Hematology Annual Meeting (GlobeNewswire) -5.32%
08:00AM	Salarius Pharmaceuticals Presents SP-3164 Data Demonstrating Activity in Preclinical Lymphoma Models at the American Society of Hematology Annual Meeting (GlobeNewswire)
Dec-08-22 08:00AM	Salarius Pharmaceuticals to Hold Conference Call to Discuss Recent Clinical and Preclinical Data on Lead Programs, Including Presentations at ASH (GlobeNewswire)
Dec-01-22 08:00AM	Salarius Pharmaceuticals Announces Interim Results from Phase 1/2 Trial of Seclidemstat as a Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas (GlobeNewswire) -5.18%
Nov-10-22 08:30AM	Salarius Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
Nov-03-22 09:57AM	Salarius Pharmaceuticals Announces Two Presentations at the 2022 American Society of Hematology Annual Meeting (GlobeNewswire)
Oct-27-22 08:30AM	Salarius Pharmaceuticals Presents Favorable Preclinical Data on SP-3164 at the 5th Annual Targeted Protein Degradation Conference (GlobeNewswire) -14.40%
Oct-19-22 08:30AM	Salarius Pharmaceuticals to Present SP-3164 at the 5th Annual Targeted Protein Degradation Conference (GlobeNewswire) -15.73%
Oct-18-22 08:30AM	Salarius Pharmaceuticals Announces Pause in New Patient Enrollment in its Phase 1/2 Trial of Seclidemstat in Ewing Sarcoma and FET-Rearranged Sarcomas (GlobeNewswire) -45.18%
Oct-14-22 08:43AM	Salarius Pharmaceuticals Announces 1-for-25 Reverse Stock Split (GlobeNewswire) -13.81%
Sep-20-22 12:00PM	Salarius Pharmaceuticals to Present at the 2022 Ladenburg Thalmann Healthcare Conference (GlobeNewswire)
Sep-13-22 08:00AM	Salarius Pharmaceuticals CEO Issues Letter to Stockholders (GlobeNewswire) +10.10%
Aug-22-22 08:30AM	Salarius Pharmaceuticals Adds Two Mayo Clinic Sites to its Ongoing Phase 1/2 Trial of Seclidemstat as a Treatment for Ewings Sarcoma and FET-Rearranged Sarcomas (GlobeNewswire) -9.29%
Aug-08-22 08:30AM	Salarius Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire) +9.95%
Aug-04-22 08:30AM	Salarius Pharmaceuticals Adds Seattle Cancer Care Alliance and Oregon Health & Sciences as Clinical Sites for its Ongoing Trial of Seclidemstat as a Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas (GlobeNewswire)
Aug-02-22 08:30AM	Salarius Pharmaceuticals and VolitionRx Enter into R&D Collaboration Agreement (GlobeNewswire) -6.07%
Jul-29-22 09:15AM	Salarius Pharmaceuticals to Host Second Quarter 2022 Financial Results and Business Update Conference Call on Monday, August 8, 2022 (GlobeNewswire)
Jun-09-22 07:33AM	Salarius Pharmaceuticals to Participate in BIO International Convention 2022 (GlobeNewswire)
May-18-22 04:10PM	Salarius Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference (GlobeNewswire) +20.62% -9.12%
May-12-22 04:05PM	Salarius Pharmaceuticals Reports Business Highlights with First Quarter 2022 Financial Results (GlobeNewswire) +38.75% -15.36%
May-11-22 04:05PM	Salarius Pharmaceuticals Completes SP-3164 Pre-Investigational New Drug Meeting Process with the U.S. Food and Drug Administration (GlobeNewswire) -16.93%
May-05-22 07:30AM	Salarius Pharmaceuticals to Report First Quarter 2022 Financial Results and Highlight Recent Company Progress (GlobeNewswire)
Apr-22-22 08:30AM	Salarius Pharmaceuticals, Inc. Announces $2.3 Million Registered Direct Offering (GlobeNewswire) -20.54%

Decoy Therapeutics, Inc. operates as a preclinical-stage biotechnology company. It engages in leveraging machine learning and AI tools alongside high-speed synthesis techniques to rapidly design, engineer and manufacture peptide conjugate drug candidates that target serious unmet medical needs. The company was founded by Frederick E. Pierce, Barbara Hibner, Peter Marschel, Michael Lipp, and Jodi Cooper in 2020 and is headquartered in Houston, TX.

CEO & DirectorMr. Frederick E. Pierce II

Executive VP of Finance & CFOMr. Mark J. Rosenblum CPA

Chief Scientific OfficerDr. Barbara Hibner Ph.D.

M.S.Mr. Peter K. Marschel M.B.A.

M.P.H.Dr. Nadeem Q. Mirza M.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
HANISH ARNOLD C	Director	Dec 30 '25	Sale	0.64	15	10	5,000	Jan 02 05:13 PM
HANISH ARNOLD C	Director	Dec 30 '25	Sale	0.64	12	8	0	Jan 02 05:13 PM
HANISH ARNOLD C	Director	Nov 20 '25	Buy	0.75	5,000	3,740	5,015	Nov 24 05:08 PM
Rosenblum Mark J	Exec VP Finance, CFO	Nov 20 '25	Buy	0.80	20,000	16,000	20,177	Nov 20 04:42 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

$100 Off Your First Year Get Elite For Just $199.50

DCOY

Decoy Therapeutics Inc

Upgrade your Finviz experience